奥氮平治疗帕金森病并发精神障碍的临床观察

目的 探讨奥氮平治疗帕金森病(PD)合并精神障碍的疗效及不良反应.方法 收集PD合并精神障碍患者96例,随机分为两组,治疗组50例,对照组46例.对照组予以调整抗帕金森药物治疗,治疗组在此基础之上加用奥氮平治疗,观察4周.治疗前后采用UPDRS评定运动功能.精神症状阳性症状量表(SAPS)评价患者精神症状程度,以SAPS减分率评定疗效.结果 两组SAPS量表评价比较,幻觉和妄想、怪异行为三项精神症状评分差异有统计学意义.UPDRS评分,治疗组治疗前后运动障碍差异无统计学意义,对照组运动障碍有统计学意义.结论 奥氮平对治疗PD并发幻觉等阳性精神症状的患者疗效肯定、安全,且不加重运动障碍.

Olanzpine in the treatment of mental disorders in Parkinson's disease

Objective To investigate the effect of olanzpine in the treatment of mental disorders in parkinson′s disease(PD).Methods 96 patients with mental disorders in parkinson′s disease were randomly assigned olanzpine group and controls group.UPDRS,SAPS scales were tested before treatment and after 4 weeks’ treatment in order to observe Symptoms including hallucinosis,deliria and abnormal behavior and dyskinesia.Results ①Compare with controls group,hallucinosis,deliria and abnormal behavior in olanzpine group were significant improved(P<0.05),②Compare to pre-treatment,dyskinesia in controls group were significant aggravated(P<0.05),but there were no statically difference in olanzpine group(P>0.05).Conclusion Olanzpine appears to an effective drug for PD patients with mental disorders,olanzpine is safe for those patients.